Logo image of PRQR

PROQR THERAPEUTICS NV (PRQR) Stock Fundamental Analysis

NASDAQ:PRQR - Nasdaq - NL0010872495 - Common Stock - Currency: USD

2.08  -0.02 (-0.95%)

Fundamental Rating

2

Overall PRQR gets a fundamental rating of 2 out of 10. We evaluated PRQR against 553 industry peers in the Biotechnology industry. Both the profitability and financial health of PRQR have multiple concerns. PRQR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRQR had negative earnings in the past year.
In the past year PRQR has reported a negative cash flow from operations.
PRQR had negative earnings in each of the past 5 years.
In the past 5 years PRQR reported 4 times negative operating cash flow.
PRQR Yearly Net Income VS EBIT VS OCF VS FCFPRQR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

PRQR's Return On Assets of -19.90% is fine compared to the rest of the industry. PRQR outperforms 77.94% of its industry peers.
With a decent Return On Equity value of -38.24%, PRQR is doing good in the industry, outperforming 71.07% of the companies in the same industry.
Industry RankSector Rank
ROA -19.9%
ROE -38.24%
ROIC N/A
ROA(3y)-24.98%
ROA(5y)-30.3%
ROE(3y)-66.23%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
PRQR Yearly ROA, ROE, ROICPRQR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRQR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRQR Yearly Profit, Operating, Gross MarginsPRQR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K -2.5K

More info and screens

3

2. Health

2.1 Basic Checks

PRQR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRQR has more shares outstanding
The number of shares outstanding for PRQR has been increased compared to 5 years ago.
PRQR has a better debt/assets ratio than last year.
PRQR Yearly Shares OutstandingPRQR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PRQR Yearly Total Debt VS Total AssetsPRQR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

PRQR has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
PRQR has a worse Debt to Equity ratio (0.14) than 67.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.08%
PRQR Yearly LT Debt VS Equity VS FCFPRQR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

PRQR has a Current Ratio of 4.10. This indicates that PRQR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.10, PRQR perfoms like the industry average, outperforming 46.29% of the companies in the same industry.
PRQR has a Quick Ratio of 4.10. This indicates that PRQR is financially healthy and has no problem in meeting its short term obligations.
PRQR's Quick ratio of 4.10 is in line compared to the rest of the industry. PRQR outperforms 48.10% of its industry peers.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 4.1
PRQR Yearly Current Assets VS Current LiabilitesPRQR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.94% over the past year.
The Revenue has grown by 45.54% in the past year. This is a very strong growth!
PRQR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 58.89% yearly.
EPS 1Y (TTM)1.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
Revenue 1Y (TTM)45.54%
Revenue growth 3Y101.19%
Revenue growth 5Y58.89%
Sales Q2Q%1.55%

3.2 Future

The Earnings Per Share is expected to decrease by -18.18% on average over the next years. This is quite bad
The Revenue is expected to grow by 45.69% on average over the next years. This is a very strong growth
EPS Next Y-25.25%
EPS Next 2Y-27.76%
EPS Next 3Y-18.18%
EPS Next 5YN/A
Revenue Next Year-12.69%
Revenue Next 2Y-20.75%
Revenue Next 3Y-24.26%
Revenue Next 5Y45.69%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PRQR Yearly Revenue VS EstimatesPRQR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
PRQR Yearly EPS VS EstimatesPRQR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRQR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRQR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRQR Price Earnings VS Forward Price EarningsPRQR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRQR Per share dataPRQR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as PRQR's earnings are expected to decrease with -18.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.76%
EPS Next 3Y-18.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRQR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROQR THERAPEUTICS NV

NASDAQ:PRQR (8/1/2025, 8:00:00 PM)

2.08

-0.02 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners40.01%
Inst Owner Change-0.16%
Ins Owners2%
Ins Owner ChangeN/A
Market Cap218.84M
Analysts85.33
Price Target9.18 (341.35%)
Short Float %0.5%
Short Ratio1.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.84%
Min EPS beat(2)-6.02%
Max EPS beat(2)0.34%
EPS beat(4)3
Avg EPS beat(4)19.46%
Min EPS beat(4)-6.02%
Max EPS beat(4)76.42%
EPS beat(8)6
Avg EPS beat(8)-75.51%
EPS beat(12)9
Avg EPS beat(12)-53.11%
EPS beat(16)11
Avg EPS beat(16)-41.39%
Revenue beat(2)0
Avg Revenue beat(2)-15.22%
Min Revenue beat(2)-28.35%
Max Revenue beat(2)-2.1%
Revenue beat(4)0
Avg Revenue beat(4)-35.62%
Min Revenue beat(4)-65.98%
Max Revenue beat(4)-2.1%
Revenue beat(8)1
Avg Revenue beat(8)-27.69%
Revenue beat(12)4
Avg Revenue beat(12)-16.14%
Revenue beat(16)8
Avg Revenue beat(16)35.11%
PT rev (1m)0%
PT rev (3m)-14.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.81%
EPS NY rev (1m)0%
EPS NY rev (3m)3.34%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)-1.2%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-14.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.78
P/FCF N/A
P/OCF N/A
P/B 2.43
P/tB 2.43
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.21
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.9%
ROE -38.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.98%
ROA(5y)-30.3%
ROE(3y)-66.23%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.12%
Cap/Sales 4.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 4.1
Altman-Z N/A
F-Score5
WACC7.08%
ROIC/WACCN/A
Cap/Depr(3y)44.7%
Cap/Depr(5y)38.73%
Cap/Sales(3y)12.15%
Cap/Sales(5y)13.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
EPS Next Y-25.25%
EPS Next 2Y-27.76%
EPS Next 3Y-18.18%
EPS Next 5YN/A
Revenue 1Y (TTM)45.54%
Revenue growth 3Y101.19%
Revenue growth 5Y58.89%
Sales Q2Q%1.55%
Revenue Next Year-12.69%
Revenue Next 2Y-20.75%
Revenue Next 3Y-24.26%
Revenue Next 5Y45.69%
EBIT growth 1Y-8.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.5%
EBIT Next 3Y15.47%
EBIT Next 5YN/A
FCF growth 1Y-868.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1019.61%
OCF growth 3YN/A
OCF growth 5YN/A